(Adnkronos) - “Nello studio Waypoint”, tezepelumab, un “anticorpo monoclonale si è dimostrato efficace nel ridurre la dimensione dei polipi, nel migliore la sensibilità olfattiva e nel ridurre gli altri sintomi associati alla malattia. Inoltre, nel 98% dei pazienti con forma severa ha ridotto la necessità di un nuovo intervento chirurgico e nell’88% nuovi cicli di corticosteroidi sistemici. Questo farmaco biologico si aggiunge quindi agli altri farmaci di questo tipo rappresentando una speranza di questi pazienti perché possono portare a una normalizzazione della loro vita portando in remissione la malattia nella maggior parte dei casi”. Così Eugenio De Corso, membro della commissione Euforea per il trattamento della rinosinusite cronica con poliposi nasale commenta i risultati dello studio che è stato presentato al congresso dell’ American Academy of Allergy Asthma & Immunology (Aaaai).
Category
🗞
NewsTranscript
00:00The chronic rhinosinusitis with nasal polyposis is a chronic disease caused by a persistent inflammation of the sinus nasopharyngeal mucosa,
00:15which determines a remodeling with the characteristic formation of polyps.
00:21This situation leads the patient to symptoms that are very invalidating, such as nasal obstruction, loss of smell, excessive mucous production and a sense of heaviness.
00:34All this has a very negative impact on the quality of the patient's life because the patient perceives this symptomatology every day.
00:44The study Waypoint has been recently published and shows the safety and effectiveness of Tezepelumab in the treatment of patients affected by severe uncontrolled rhinosinus polyposis.
01:00Tezepelumab is a molecule capable of binding TSLP, which is a cytokine produced by the nasal epithelium and which is able to initiate the chronic inflammatory process of the nasal mucosa in these patients and which is able to make it chronic.
01:20Tezepelumab in this study has been shown to be effective in reducing the size of the polyps, in significantly improving olfactory sensitivity and in reducing other symptoms associated with the disease.
01:37In addition, Tezepelumab, in this particular category of patients who are severely ill, has been shown to be effective in reducing, for 98% of them, the need for a new surgical intervention and for 88% of them to reduce the need for systemic corticosteroids.
02:01In fact, patients affected by severe form unfortunately in the past needed more surgical interventions and more cycles of systemic corticosteroids.
02:14Instead, in this study, Tezepelumab has been shown to be effective in reducing, for most patients, the need for new interventions and the need for new cycles of systemic corticosteroids.
02:28These results are very important, especially in light of the fact that repeated cycles of systemic corticosteroids are associated with side effects in the short and long term.
02:42In recent years, the treatment of this pathology has changed significantly thanks to research and thanks to the results of research, because it has led to the commercialization of new biological drugs.
02:57These drugs have the ability to completely extinguish the chronic inflammation associated with the disease, leading to the remission of a very high percentage of patients that we could not control properly before.
03:14Tezepelumab is added to the biological drugs already available and these drugs represent hope for patients, because they can lead to a normalization of their lives, leading to the remission of the disease in most cases.